Birmingham, West Midlands -- (SBWIRE) -- 12/19/2013 -- Value Penny Stocks issues special report on Orexigen Therapeutics, Inc. (NASDAQ:OREX), GT Advanced Technologies Inc (NASDAQ:GTAT), Opexa Therapeutics Inc(NASDAQ:OPXA), MannKind Corporation (NASDAQ:MNKD).
Orexigen Therapeutics, Inc. (NASDAQ:OREX) opened its last trade at the price of $5.38. Its closing price was $5.46 after gaining 1.49% for the day. The company traded with the total volume of 3,720,650 shares, while its average trading volume remained 2.80 million shares. The beta of this stock stands at 2.14. Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include Contrave, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic, which has completed Phase II clinical trials.
For How Long OREX will Fight for Profitability? Read This Trend Analysis report
GT Advanced Technologies Inc (NASDAQ:GTAT) percentage change plunged -0.12% to close at $8.49 with the total traded volume of 3,670,794 shares, along with average volume of 7.05 million shares. The 52 week range of the stock remained $2.61 - $10.75, while its day lowest price was $8.22. The share price hit the day highest price of $8.58. GT Advanced Technologies Inc. provides crystal growth equipment and solutions for the solar, light emitting diode (LED), and electronics industries worldwide. The company operates through three segments: Polysilicon; Photovoltaic (PV); and Sapphire.
Has GTAT Found The Bottom And Ready To Gain Momentum? Find Out Here
Opexa Therapeutics Inc(NASDAQ:OPXA) traded on volume of 3,589,274 shares in the last session against average volume of 571,235.00 shares. The company started its trading session with the price of $1.70 and closed at $1.68 by scoring -10.64%. Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized cellular therapies to treat multiple sclerosis (MS) based on its proprietary T-cell technology. Its leading therapy candidate includes Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS.
Why Should Investors Buy OPXA After the Recent Fall? Just Go Here and Find Out
MannKind Corporation (NASDAQ:MNKD) started its last trading session with the price of $4.96 and closed at $4.96 by scoring 0.43%. The stock traded with total volume of 3,493,934 shares, while the average trading volume remained 4.29 million shares. The beta value of this stock stands at 1.87. Day range for the stock was $4.85 - $5.00. MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States.
Why Should Investors Buy MNKD After The Recent Gain? Just Go Here and Find Out
About Value Penny Stocks
Value Penny Stocks was made by Two Active traders, Steve and Wilson, whom have made a platform for traders in order to provide traders the #1 Penny Stock Newsletter which actually gives value to your money and makes your portfolio full of profits. We concentrate on small cap stocks that trade on NYSE, NASD, AMEX, OTCBB, and OTC exchanges. These are usually stocks that will trade under $5 a share and offer the utmost potential profit on your short or long term investment. We also devote ourselves to understanding the overall market situations and use this knowledge in order to gain a better perception during our stock picking decisions.
We at ValuePennyStocks.com are engaged in the business of marketing and advertising companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Please Read Our Full Disclaimer at: http://www.valuepennystocks.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)